drugset / Trial / NCT00894803
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke
Phase 2
Completed
126 enrolled
University of Cincinnati
National Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a medium dose of IV rt-PA plus IV eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome than individuals treated with standard IV rt-PA alone.
Timeline
- Start
- 2009-07
- Primary completion
- 2012-10
- Completion
- 2012-12
Publications
- Background Barreto AD, Pedroza C, Grotta JC. Adjunctive medical therapies for acute stroke thrombolysis: is there a CLEAR-ER choice? Stroke. 2013 Sep;44(9):2377-9. doi: 10.1161/STROKEAHA.113.001830. Epub 2013 Jul 25. No abstract available.
- Results Pancioli AM, Adeoye O, Schmit PA, Khoury J, Levine SR, Tomsick TA, Sucharew H, Brooks CE, Crocco TJ, Gutmann L, Hemmen TM, Kasner SE, Kleindorfer D, Knight WA, Martini S, McKinney JS, Meurer WJ, Meyer BC, Schneider A, Scott PA, Starkman S, Warach S, Broderick JP; CLEAR-ER Investigators. Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial. Stroke. 2013 Sep;44(9):2381-7. doi: 10.1161/STROKEAHA.113.001059. Epub 2013 Jul 25.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eptifibatide | Other / unclassified | 0.75 ug/kg | Intravenous |
| Subject | recombinant tissue plasminogen activator | Protein / enzyme biologic | 0.6 mg/kg | Intravenous |
| Subject | recombinant tissue plasminogen activator | Protein / enzyme biologic | 0.9 mg/kg | Intravenous |